Published in Nihon Naika Gakkai Zasshi on June 10, 2003
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull (2006) 4.42
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2008) 4.26
Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol (2008) 3.12
Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci (2007) 2.61
Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol (2009) 2.52
MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep (2006) 2.29
Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res (2007) 2.25
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol (2005) 2.24
MicroRNA-143 and -145 in colon cancer. DNA Cell Biol (2007) 2.24
Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology (2009) 2.21
EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood (2011) 2.18
Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med (2012) 2.06
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood (2003) 1.87
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol (2008) 1.81
Integrin activation and matrix binding mediate cellular responses to mechanical stretch. J Biol Chem (2005) 1.80
Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood (2011) 1.79
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood (2005) 1.66
Nicorandil promotes myocardial capillary and arteriolar growth in the failing heart of Dahl salt-sensitive hypertensive rats. Hypertension (2005) 1.62
Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res (2010) 1.59
Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene (2002) 1.56
Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia. Cancer Sci (2012) 1.48
Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients. Cancer Sci (2010) 1.46
Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol Ther (2010) 1.43
Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer (2005) 1.42
MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett (2011) 1.42
Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation study. Leuk Res (2012) 1.42
Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett (2010) 1.42
Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ J (2007) 1.41
Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J Exp Med (2003) 1.40
BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci U S A (2008) 1.34
Characterized mechanism of alpha-mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells. Bioorg Med Chem (2007) 1.33
Targeted disruption of mouse ortholog of the human MYH9 responsible for macrothrombocytopenia with different organ involvement: hematological, nephrological, and otological studies of heterozygous KO mice. Biochem Biophys Res Commun (2004) 1.27
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood (2009) 1.21
Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol (2007) 1.20
Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. Int J Hematol (2013) 1.14
BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol (2005) 1.13
Molecular evaluation of endothelial progenitor cells in patients with ischemic limbs: therapeutic effect by stem cell transplantation. Arterioscler Thromb Vasc Biol (2004) 1.12
Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochem Biophys Res Commun (2009) 1.12
Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation. Oncogene (2003) 1.12
Evaluation of organ involvement in intravascular large B-cell lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Int J Hematol (2008) 1.11
Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia. Eur J Haematol (2009) 1.08
CD56/NCAM-positive Langerhans cell sarcoma: a clinicopathologic study of 4 cases. Int J Hematol (2005) 1.08
Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells. Leuk Res (2009) 1.08
Transforming mutations of RAC guanosine triphosphatases in human cancers. Proc Natl Acad Sci U S A (2013) 1.07
Adipose tissue-derived mesenchymal stem cells facilitate hematopoiesis in vitro and in vivo: advantages over bone marrow-derived mesenchymal stem cells. Am J Pathol (2010) 1.06
Tumor-suppressive microRNA-145 targets catenin δ-1 to regulate Wnt/β-catenin signaling in human colon cancer cells. Cancer Lett (2013) 1.05
Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci (2002) 1.05
Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. Blood (2003) 1.05
PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia. Leuk Res (2006) 1.05
Acute myeloid leukemia in older adults. Int J Hematol (2012) 1.03
Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica (2008) 1.02
A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. Leuk Res (2011) 1.01
PML-retinoic acid receptor alpha inhibits PML IV enhancement of PU.1-induced C/EBPepsilon expression in myeloid differentiation. Mol Cell Biol (2007) 1.00
A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations. Clin Cancer Res (2007) 1.00
A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation. Br J Haematol (2005) 1.00
Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy. Int J Hematol (2008) 1.00
Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood (2013) 0.98
Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood (2012) 0.97
Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. Int J Hematol (2006) 0.97
FLT3 in human hematologic malignancies. Leuk Lymphoma (2002) 0.96
Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma. Int J Hematol (2006) 0.96
Identification of non-coding RNAs embracing microRNA-143/145 cluster. Mol Cancer (2010) 0.96
Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol (2008) 0.94
Cyclin C regulates human hematopoietic stem/progenitor cell quiescence. Stem Cells (2010) 0.93
Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis. J Biol Chem (2008) 0.93
Hematopoietic engraftment in recipients of unrelated donor umbilical cord blood is affected by the CD34+ and CD8+ cell doses. Biol Blood Marrow Transplant (2007) 0.93
Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines. Cancer Sci (2006) 0.92
Antitumor effect of arsenic trioxide in murine xenograft model. Cancer Sci (2003) 0.92
Epigenetic regulation of microRNA-128a expression contributes to the apoptosis-resistance of human T-cell leukaemia jurkat cells by modulating expression of fas-associated protein with death domain (FADD). Biochim Biophys Acta (2014) 0.92
Chemically modified synthetic microRNA-205 inhibits the growth of melanoma cells in vitro and in vivo. Mol Ther (2013) 0.91
A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403. Transplantation (2007) 0.91
Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single-center experience. Eur J Haematol (2005) 0.90
Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci (2012) 0.89
Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo. Biochem Biophys Res Commun (2006) 0.89
Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematol (2007) 0.89
Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. Cancer Sci (2010) 0.88
Microvesicles released from hormone-refractory prostate cancer cells facilitate mouse pre-osteoblast differentiation. J Mol Histol (2012) 0.88
Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia. Clin Cancer Res (2013) 0.87
BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4. Eur J Haematol (2009) 0.87
Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. Int J Hematol (2011) 0.87
Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol (2009) 0.87
The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0. Int J Hematol (2010) 0.87
A novel RUNX1-C11orf41 fusion gene in a case of acute myeloid leukemia with a t(11;21)(p14;q22). Cancer Genet (2012) 0.87
Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor. Int J Hematol (2006) 0.86
Irrespective of CD34 expression, lineage-committed cell fraction reconstitutes and re-establishes transformed Philadelphia chromosome-positive leukemia in NOD/SCID/IL-2Rgammac-/- mice. Cancer Sci (2009) 0.86
Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study. Int J Hematol (2012) 0.86
DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells. Biochim Biophys Acta (2013) 0.86
Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group. Int J Hematol (2008) 0.86
Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma. Int J Hematol (2006) 0.86
Y654 of β-catenin is essential for FLT3/ITD-related tyrosine phosphorylation and nuclear localization of β-catenin. Eur J Haematol (2012) 0.86
SFK-STAT pathway: an alternative and important way to malignancies. Ann N Y Acad Sci (2006) 0.86